蔚蓝生物
(603739)
| 流通市值：39.50亿 | | | 总市值：39.50亿 |
| 流通股本：2.53亿 | | | 总股本：2.53亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,015,793,037.32 | 652,193,328.83 | 310,197,929.93 | 1,320,761,061.74 |
| 营业收入 | 1,015,793,037.32 | 652,193,328.83 | 310,197,929.93 | 1,320,761,061.74 |
| 二、营业总成本 | 946,888,887.21 | 611,538,303.12 | 293,945,014.79 | 1,222,005,770.44 |
| 营业成本 | 564,304,405.47 | 358,237,347.47 | 172,593,365.91 | 725,808,660.93 |
| 税金及附加 | 10,745,176.45 | 6,765,761.08 | 3,400,130.96 | 13,221,888.06 |
| 销售费用 | 154,231,257.39 | 105,168,275.54 | 49,401,628.1 | 197,380,400.84 |
| 管理费用 | 104,152,866.56 | 68,690,483.58 | 35,652,170.83 | 146,598,499.14 |
| 研发费用 | 100,238,559.8 | 63,882,939.04 | 28,494,054.14 | 118,222,310.22 |
| 财务费用 | 13,216,621.54 | 8,793,496.41 | 4,403,664.85 | 20,774,011.25 |
| 其中:利息费用 | 12,413,825.03 | 11,699,465.59 | 4,282,179.3 | 21,878,828.93 |
| 其中:利息收入 | -584,054.38 | -422,077.03 | -147,205.94 | 1,525,111.73 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 28,410,589.39 | 4,166,982.33 | 495 | 8,317,637.54 |
| 加:投资收益 | -1,198,744.89 | -126,522.53 | 1,661,922.5 | -1,239,485.35 |
| 资产处置收益 | 398,570.39 | 393,279.13 | - | 602,390.96 |
| 资产减值损失(新) | 863,811.28 | 860,799.97 | 167,960.88 | -2,684,134.98 |
| 信用减值损失(新) | -8,576,208.89 | -2,960,723.86 | 2,258,789.16 | -6,467,361.25 |
| 其他收益 | 20,752,969.81 | 10,959,304.49 | 4,247,123.77 | 26,739,205.79 |
| 四、营业利润 | 109,555,137.2 | 53,948,145.24 | 24,589,206.45 | 124,023,544.01 |
| 加:营业外收入 | 349,969.29 | 325,758.6 | 218,331.98 | 81,583.65 |
| 减:营业外支出 | 1,521,274.18 | 1,198,953.67 | 434,093.59 | 661,210.77 |
| 五、利润总额 | 108,383,832.31 | 53,074,950.17 | 24,373,444.84 | 123,443,916.89 |
| 减:所得税费用 | 25,453,996.23 | 13,270,532.7 | 7,787,082.66 | 31,271,642.41 |
| 六、净利润 | 82,929,836.08 | 39,804,417.47 | 16,586,362.18 | 92,172,274.48 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 82,929,836.08 | 39,804,417.47 | 16,586,362.18 | 92,172,274.48 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 61,779,150.1 | 26,716,293.11 | 9,576,827.68 | 62,637,482.98 |
| 少数股东损益 | 21,150,685.98 | 13,088,124.36 | 7,009,534.5 | 29,534,791.5 |
| 扣除非经常损益后的净利润 | 22,933,229.79 | 16,002,005.78 | 5,259,509.61 | 25,154,344.46 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.24 | 0.11 | 0.04 | 0.25 |
| (二)稀释每股收益 | 0.24 | 0.11 | 0.04 | 0.25 |
| 八、其他综合收益 | -219,343.11 | -166,749.78 | - | 1,256,980.5 |
| 归属于母公司股东的其他综合收益 | -169,834.31 | -134,355.02 | - | 1,271,958.72 |
| 九、综合收益总额 | 82,710,492.97 | 39,637,667.69 | 16,586,362.18 | 93,429,254.98 |
| 归属于母公司股东的综合收益总额 | 61,609,315.79 | 26,581,938.09 | 9,576,827.68 | 63,909,441.7 |
| 归属于少数股东的综合收益总额 | 21,101,177.18 | 13,055,729.6 | 7,009,534.5 | 29,519,813.28 |
| 公告日期 | 2025-10-29 | 2025-08-28 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |